28 March 2025 in Production and Operations Management
Generic drugs provide lifesaving, affordable treatment to millions of people each day. Generic drug manufacturing has been steadily moving from advanced economies, such as the U.S., to emerging economies, such as India. Due to the opacity of drug supply chains, the quality risk implications of manufacturing in emerging economies have not been carefully empirically tested. This study addresses this gap. To do so, we identify a novel source of drug manufacturing location data that allows us to compare the occurrence of serious adverse events of generic drugs made in different locations. Using exact matching analyses based on the equivalency criteria established by the U.S. Food and Drug Administration, we find that generic drugs manufactured in India, where a majority of emerging economy generic drugs are made, are associated with significantly higher instances of serious adverse events than equivalent generic drugs made in the U.S., where a majority of advanced economy generic drugs are made. We further show that this key result is explained by mature generic drugs, which are particularly susceptible to operations and supply chain cost reduction efforts—efforts that unfortunately may compromise drug quality. Our study finding leads to implications for the FDA in their regulation of generic drugs.
8 October 2024 in Journal of Operations Management
Drug shortages have been persistent in the United States for over a decade, posing serious threats to public health and the healthcare system. While previous research has investigated the causes and effects of drug shortages, there is a dearth of research exploring potential solutions to mitigate this problem. Using a system dynamics model of the US generic drug market, we evaluate the long‐term effectiveness of two existing policy interventions (expediting drug approvals and nudging manufacturers to ramp up their production) and the “quality reward” initiative that is being actively explored by the FDA and industry. Our results indicate that while the existing interventions can be helpful in addressing shortages, their long‐term effect seems limited. In contrast, quality reward can mitigate drug shortages in a sustainable way. However, a caveat of quality reward is the potential emergence of a monopolistic supply market with negative consequences. We suggest that a carefully designed quality disclosure mechanism can address this issue. To the best of our knowledge, this is the first study to quantitatively and comparatively evaluate the long‐term effectiveness of quality reward and other interventions on drug shortages and provide structural explanations for their performance.
28 May 2026 in Management Science
U.S. hospitals continue to face chronic shortages of essential drugs, jeopardizing patient care and driving up costs. Although prior work has identified the structural and economic drivers of these shortages, little is known about whether pharmaceutical plants accumulate operational knowledge from their recovery efforts—tasks that are often irregular and ill-defined. We assemble a unique data set linking 4,741 drug shortages (2015–2020) to 136 finished dosage form plants to examine whether—and under what conditions—plants learn from past recoveries. Using an instrumental variables approach, we find that each additional shortage a plant has previously resolved significantly reduces its time to recovery for a current shortage, indicating cumulative learning. We further show that learning is concentrated in shortages caused by internal plant issues, with no such effect for externally induced disruptions. Breadth of experience also matters; learning gains are larger when prior recoveries span diverse active ingredients or causal categories. Post hoc analyses reveal that the knowledge gained is confined largely to the focal plant and does not readily transfer across facilities within the same firm. These findings suggest that structured knowledge-capture processes, cross-site learning mechanisms, and incentives to diversify recovery experience can strengthen supply chain resilience. This paper was accepted by Stefan Scholtes, healthcare management. Supplemental Material: The online appendix and data files are available at https://doi.org/10.1287/mnsc.2024.08337 .